IL85609A - Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation - Google Patents

Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation

Info

Publication number
IL85609A
IL85609A IL85609A IL8560988A IL85609A IL 85609 A IL85609 A IL 85609A IL 85609 A IL85609 A IL 85609A IL 8560988 A IL8560988 A IL 8560988A IL 85609 A IL85609 A IL 85609A
Authority
IL
Israel
Prior art keywords
ethyl
phenyl
carbamate
dimethylamino
salts
Prior art date
Application number
IL85609A
Other languages
English (en)
Other versions
IL85609A0 (en
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL85609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL85609A0 publication Critical patent/IL85609A0/xx
Publication of IL85609A publication Critical patent/IL85609A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL85609A 1987-03-04 1988-03-02 Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation IL85609A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (2)

Publication Number Publication Date
IL85609A0 IL85609A0 (en) 1988-08-31
IL85609A true IL85609A (en) 1992-07-15

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85609A IL85609A (en) 1987-03-04 1988-03-02 Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation

Country Status (29)

Country Link
US (1) US5602176A (fr)
JP (3) JP2625478B2 (fr)
KR (1) KR0133686B1 (fr)
AT (1) AT394190B (fr)
AU (1) AU618949B2 (fr)
BE (1) BE1001467A3 (fr)
CA (1) CA1307003C (fr)
CH (1) CH675720A5 (fr)
CS (1) CS411091A3 (fr)
CY (1) CY1735A (fr)
DK (1) DK175762B1 (fr)
ES (1) ES2010527A6 (fr)
FI (1) FI89165C (fr)
FR (1) FR2611707B1 (fr)
GB (1) GB2203040C (fr)
GR (1) GR1000023B (fr)
HK (1) HK110093A (fr)
HU (1) HU201906B (fr)
IE (1) IE61714B1 (fr)
IL (1) IL85609A (fr)
IT (1) IT1219853B (fr)
LU (2) LU87150A1 (fr)
MY (1) MY103225A (fr)
NL (1) NL195004C (fr)
NZ (1) NZ223714A (fr)
PT (1) PT86875B (fr)
SA (1) SA93140384B1 (fr)
SE (1) SE8800731L (fr)
ZA (1) ZA881584B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5712282A (en) * 1994-04-15 1998-01-27 Masaomi Iyo Method for therapeutically treating tardive dyskinesia and uses thereof
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
EP0951284B1 (fr) * 1996-12-18 2003-10-08 Teva Pharmaceutical Industries, Ltd. Derives de phenylethylamine
HU229507B1 (en) 1996-12-18 2014-01-28 Technion Res & Dev Foundation 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
NZ510683A (en) 1998-10-01 2003-09-26 Novartis Ag Sustained release oral formulations of rivastigmine
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
WO2000033840A1 (fr) * 1998-12-11 2000-06-15 Bonnie Davis Utilisation d'inhibiteurs d'acetylcholine esterase pour la modulation de l'axe hypothalamo-hypophyso-gonadique
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
EP1856036B1 (fr) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited Procede efficace de preparation de (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE543545T1 (de) 2005-09-15 2012-02-15 Sony Computer Entertainment Inc Beschaffung einer eingabe zum kontrollieren der ausführung eines spielprogrammes
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CA2634166C (fr) * 2005-12-09 2016-03-29 Marta Weinstock-Rosin Utilisation de ladostigil a faible dose pour la neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (fr) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Traitement de troubles psychiatriques
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (fr) 2006-09-29 2008-04-03 Synthon B.V. Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
CA2667553A1 (fr) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Procedes et combinaison de therapies pour le traitement de la maladie d'alzheimer
EP1942100A1 (fr) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Formes amorphes et cristallines dýhydrogénotartrate de rivastigmine
EP2125709A2 (fr) * 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Composes inhibiteurs de cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (fr) * 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Procédé de préparation de rivastigmine, ses intermédiaires et procédé de préparation des intermédiaires
WO2010023535A1 (fr) 2008-08-25 2010-03-04 Jubilant Organosys Limited Procédé de production de (s)-3-[(1-diméthylamino)éthyl]phényl-n-éthyl-n-méthyl-carbamate par le biais de nouveaux intermédiaires
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
WO2011076621A2 (fr) 2009-12-22 2011-06-30 Acino Ag Système thérapeutique transdermique servant à administrer de la rivastigmine ou ses dérivés
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (fr) 2010-02-09 2019-01-15 Michela Gallagher Procedes et compositions pour ameliorer la fonction cognitive
JP6088422B2 (ja) 2010-03-29 2017-03-01 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
WO2011151669A1 (fr) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
WO2011159910A2 (fr) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalyseurs et procédés pour la synthèse de (s)-3-(1-aminoéthyl)-phénol
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
SI2468274T1 (sl) 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
EP2752188B1 (fr) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Timbre transdermique
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (fr) 2011-11-18 2013-05-22 Labtec GmbH Composition pour administration transdermique de rivastigmine
WO2013142339A1 (fr) 2012-03-23 2013-09-26 Novartis Ag Système thérapeutique transdermique et procédé associé
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (fr) 2013-01-15 2014-07-24 Zydus Technologies Limited Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (fr) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam pour améliorer la fonction cognitive
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
DK3033082T3 (da) 2013-08-16 2021-09-20 Univ Maastricht Behandling af kognitiv svækkelse med pde4-hæmmer
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
DK112588A (da) 1988-09-05
FI89165C (fi) 1993-08-25
FR2611707B1 (fr) 1990-04-20
JPH09165362A (ja) 1997-06-24
SE8800731A0 (sv) 1988-09-05
NL195004B (nl) 2003-07-01
KR0133686B1 (ko) 1998-04-21
GB2203040B (en) 1990-10-24
AU1255488A (en) 1988-09-08
CH675720A5 (fr) 1990-10-31
JPH09118617A (ja) 1997-05-06
NL8800436A (nl) 1988-10-03
SE8800731L (sv) 1988-09-05
ATA55188A (de) 1991-08-15
IE880583L (en) 1988-09-04
BE1001467A3 (fr) 1989-11-07
SA93140384B1 (ar) 2006-04-04
HUT49325A (en) 1989-09-28
GR880100125A (en) 1989-01-31
SE8800731D0 (sv) 1988-03-02
NZ223714A (en) 1994-05-26
LU87150A1 (fr) 1988-11-17
CY1735A (en) 1994-06-03
IL85609A0 (en) 1988-08-31
FI880972A0 (fi) 1988-03-02
AU618949B2 (en) 1992-01-16
IT8847693A0 (it) 1988-03-04
PT86875A (pt) 1988-04-01
PT86875B (pt) 1992-05-29
GB2203040A (en) 1988-10-12
US5602176A (en) 1997-02-11
IE61714B1 (en) 1994-11-30
DK175762B1 (da) 2005-02-14
HU201906B (en) 1991-01-28
DK112588D0 (da) 1988-03-02
CA1307003C (fr) 1992-09-01
MY103225A (en) 1993-05-29
GR1000023B (el) 1990-01-31
IT1219853B (it) 1990-05-24
FI89165B (fi) 1993-05-14
KR880011088A (ko) 1988-10-26
ES2010527A6 (es) 1989-11-16
JP2859225B2 (ja) 1999-02-17
NL195004C (nl) 2003-11-04
FI880972A (fi) 1988-09-05
GB8804888D0 (en) 1988-03-30
GB2203040C (en) 2014-07-30
HK110093A (en) 1993-10-29
AT394190B (de) 1992-02-10
ZA881584B (en) 1989-11-29
JP2625478B2 (ja) 1997-07-02
JPS63238054A (ja) 1988-10-04
CS411091A3 (en) 1992-12-16
LU90297I2 (fr) 1998-12-07
FR2611707A1 (fr) 1988-09-09

Similar Documents

Publication Publication Date Title
IL85609A (en) Pharmaceutical compositions containing phenyl carbamates for systemic transdermal applications,(s)-n-ethyl-3-((1-dimethylamino)ethyl)-n-methyl-phenyl-carbamate and salts thereof and their preparation
EP0236624A3 (en) Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them
IL62018A0 (en) Agmatine derivatives,their preparation and pharmaceutical compositions containing them
HK18796A (en) New amino acid derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
HUT40143A (en) Process for preparing n,n-dialkyl-guanidino-dipeptide derivatives and pharmaceutical compositions containing thereof as active substances
HK18194A (en) Substituted benzamide derivatives,processes for the preparation thereof,and pharmaceutical compositions containing the same
PT84737A (en) N-(2(-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them
IL87080A (en) 4-amino-5-halo 2,n-disubstituted benzamides,their preparation and pharmaceutical compositions containing them
IL75197A0 (en) Aminotetralin derivatives,their preparation and pharmaceutical compositions containing them
GB2053909B (en) Pyrrolidinylalkycarboxylic acid amide derivatives their preparation and pharmaceutical compositions containing them
IL83432A0 (en) Phenyl butenamide derivatives,their preparation and pharmaceutical compositions containing them
IL59425A (en) Pharmaceutical compositions comprising n-substituted aziridine-2-carboxylic acid derivatives,certain such compounds and their preparation
IL71185A (en) Pharmaceutical compositions comprising n-(piperidinyl-alkyl))carboxamides,some such novel compounds and their preparation
IL86244A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL80106A0 (en) Arylmethylazoles and their salts,processes for their preparation and pharmaceutical compositions containing them
IL75794A (en) 2-hydroxy-5-(1-hydroxy-2-(aralkyloxyalkylamino)ethyl)aniline derivatives,their preparation and pharmaceutical compositions containing them
GB2064514B (en) Flavan compounds and acid addition salts thereof and pharmaceutical compositions thereof
IL79222A0 (en) 2-oxy-4h-3,1-benzoxazin-4-one derivatives and related compounds,their preparation and pharmaceutical compositions containing them
IL79792A (en) Amino acid derivatives,their preparation and pharmaceutical compositions containing them
IL88446A0 (en) Substituted hydroxylamines,their preparation and pharmaceutical compositions containing them
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL86411A0 (en) Catecholamine derivatives,their preparation and pharmaceutical compositions containing them
IL66227A (en) N-(2-(5-dimethylaminomethyl-furan-2-yl-methylthio)-ethyl)-benzamide derivatives and their salts,their preparation and pharmaceutical compositions containing them
PH15697A (en) 2-acetoxymethyl-2-methyl-(5r)-penam-3a-carboxylic acid,base salts thereof and pharmaceutical compositions containing same
IL68872A0 (en) N-(2-methoxyethyl)-noroxymorphone and salts thereof,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTG Extension of patent term granted
KB Patent renewed
EXTN Extension order renewed
EXTN Extension order renewed
EXP Patent expired